Drug intelligence / Profile preview

thv01-1

Development stage: Unknown
Lead developer: Theravectys
Modality: Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

THV01-1 is a therapeutic HIV vaccine component based on lentiviral vector technology. It contains genes encoding epitopes of the HIV-1 Gag, Pol, and Nef proteins. The vaccine is designed to elicit a broad and long-lasting cellular immune response against HIV-1 epitopes. When administered, the antigen it encodes will be expressed and cleaved into epitopes that will be exposed at the cells' surface, leading to elimination of cells infected by HIV. THV01-1 is administered intramuscularly as part of the THV01 vaccine treatment, which consists of both THV01-1 and THV01-2 vaccines given eight weeks apart.

Targets

HIV-1 Gag/Pol/Nef peptide-MHC complex

Beyond the preview

Go deeper on thv01-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thv01-1.

Explore the full profile